IP Library Granted Patent US 9,511,113
Granted Patent B2
US 9,511,113 · App. 14/748,185 · Granted Dec 6, 2016

Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions

Inventors: Rutledge Ellis-Behnke (Canton, MA); Yu-Xiang Liang (Hong Kong, CN); Gerald E. Schneider (Somerville, MA); Kwok-Fai So (Hong Kong, CN); David K. C. Tay (Hong Kong, CN)
Assignees: Massachusetts Institute of Technology; Versitech Limited
A61K38/10A61L15/42A61L26/0061
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,511,113
App. No.
14/748,185
Granted
Dec 6, 2016
Kind
B2
Abstract

Method are described for inhibiting movement of a bodily fluid and/or contaminants on or in an animal comprising administering to the animal self-assembling peptidomimetics, including α-peptides, β-peptides, γ-peptides, and/or δ-peptides.

Claims (28)

1. A method for inhibiting movement of a bodily fluid and/or contaminant on or in an animal, comprising:

administering a composition to a portion of an animal prior to, during, and/or after the occurrence of a surgical incision or wound to the animal,

wherein the composition comprises self-assembling peptidomimetics in an amount and concentration effective to substantially inhibit movement of the bodily fluid and/or contaminant,

wherein the self-assembling peptidomimetics are selected from the group consisting of α-peptides, β-peptides, γ-peptides, and δ-peptides, and a combination of more than one of these,

wherein the α-peptide peptidomimetics are selected from the group consisting of N,N′-linked oligoureas, oligopyrrolinones, oxazolidin-2-ones, azatides and azapeptides; and

wherein the composition forms a structure that inhibits movement of the bodily fluid and/or contaminant upon interaction with at least one ionic species present in or on the animal.

2. A method as in claim 1 , wherein the composition is administered by spraying, injection, infusion, dusting, painting, dipping, or coating, or orally, enterally, parenterally, topically, locally, regionally, or as an enema or suppository.

3. A method as in claim 1 , wherein the composition is in the form of a gel, solution, suspension, or an emulsion.

4. A method as in claim 1 , wherein the structure provides an optically transparent environment on or within the portion of the animal.

5. A method as in claim 1 , wherein irrigation of the portion of the animal with saline is not carried out prior to, during, and/or after the occurrence of a surgical incision or wound to the animal.

6. A method as in claim 1 , wherein the portion of the animal is within or adjacent to an organ selected from the group consisting of skin, a blood vessel, lung, dura, intestines, stomach, heart, biliary tract, urinary tract, esophagus, brain, spinal cord, gastrointestinal tract, liver, muscle, artery, vein, nervous system, eye, ear, nose, mouth, pharynx, respiratory system, cardiovascular system, digestive system, urinary system, reproductive system, musculoskeletal system, and liver.

7. A method as in claim 1 , wherein the composition is administered during resection of a tumor.

8. A method as in claim 1 , wherein the composition is administered during repair of a cornea.

9. A method as in claim 1 , wherein the composition is administered to a portion of the animal to inhibit bleeding.

10. A method as in claim 1 , wherein the composition is administered to maintain the body temperature of a patient.

11. A method as in claim 1 , wherein the composition is administered to an aneurysm.

12. A method as in claim 1 , wherein the composition is administered to an ulcer.

13. A method as in claim 1 , wherein the composition is administered to a burn.

14. A method as in claim 1 , wherein the structure inhibits movement of a contaminant such that an immune response of the animal to the contaminant is reduced relative to an immune response of the animal to the contaminant in the absence of the structure.

15. A method as in claim 1 , wherein the composition further comprises a coloring agent.

16. A method for inhibiting movement of a bodily fluid and/or contaminant on or in an animal, comprising:

administering, to a portion of an animal prior to, during, and/or after the occurrence of a surgical incision or wound to the animal, in combination:

a composition comprising self-assembling peptidomimetics in an amount and concentration effective to substantially inhibit movement of the bodily fluid and/or contaminant, wherein the self-assembling peptidomimetics are selected from the group consisting of α-peptides, β-peptides, γ-peptides, and δ-peptides, and a combination of more than one of these, wherein the α-peptide peptidomimetics are selected from the group consisting of N,N′-linked oligoureas, oligopyrrolinones, oxazolidin-2-ones, and azatides and azapeptides; and

a solution which, when combined with the composition, dissolves or hydrates the materials to form a material capable of inhibiting movement of a bodily fluid and/or contaminant.

17. A method for inhibiting movement of a contaminant, comprising:

applying a composition to a surface of a component, the component comprising a medical device or other article,

wherein the composition comprises self-assembling peptidomimetics in an amount and concentration effective to substantially inhibit movement of a contaminant on the surface of the component relative to the component, wherein the self-assembling peptidomimetics are selected from the group consisting of α-peptides, β-peptides, γ-peptides, and δ-peptides, and a combination of more than one of these, wherein the α-peptide peptidomimetics are selected from the group consisting of N,N′-linked oligoureas, oligopyrrolinones, oxazolidin-2-ones, and azatides and azapeptides; and

wherein the composition forms a structure that inhibits movement of the bodily fluid and/or contaminant upon interaction with at least one ionic species present in or on the animal.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: THE UNIVERSITY OF HONG KONG
To: VERSITECH LIMITED
Reel/Frame 040029/0127 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2016
From: ELLIS-BEHNKE, RUTLEDGE; SCHNEIDER, GERALD E.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 040004/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2016
From: LIANG, YU-XIANG; SO, KWOK-FAI; TAY, DAVID
To: THE UNIVERSITY OF HONG KONG
Reel/Frame 040004/0340 →
CONFIRMATORY LICENSE Recorded Aug 20, 2015
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036408/0072 →
Continuity (3)
Division 11796132 · Apr 25, 2007
Provisional Application 60745601 · Apr 25, 2006
Related Publication 20150328279A1 · Nov 19, 2015